Status:
UNKNOWN
Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
Lead Sponsor:
Korea University Guro Hospital
Collaborating Sponsors:
Ajou University School of Medicine
Hallym University Kangnam Sacred Heart Hospital
Conditions:
COVID-19 Vaccination
Inflammation
Eligibility:
All Genders
19-59 years
Brief Summary
Analysis of humoral antibody and cytokine kinetics after vaccination with either BNT162b2 or ChAdOx1 nCoV-19 vaccine and factors influencing the vaccine immunogenicity
Detailed Description
There is a different aspect of reactogenicity between BNT162b2 and ChAdOx1 nCoV-19 vaccine. Both new platform vaccines were concerned if they would elicit more significant local or systemic reactogeni...
Eligibility Criteria
Inclusion
- Volunteers who provide the informed consent after either BNT162b2 or ChAdOx1 vaccination
- healthy adults without underlying medical condition
Exclusion
- Volunteers who had ever infected with SARS-CoV2 were excluded.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05315856
Start Date
March 1 2021
End Date
December 31 2022
Last Update
April 7 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Ajou University School of Medicine
Suwon, Gyeonggi-do, South Korea
2
Kangnam Sacred Heart Hospital
Seoul, South Korea
3
Korea University Guro Hospital
Seoul, South Korea